Your message has been sent to our team.
Annual Reports 10-K
A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission, that gives a comprehensive summary of a company's financial performance over the course of one year. We filed our first annual report as "Marizyme, Inc." on March 5, 2019 for the year ended December 31, 2018 and our second annual report as Marizyme, Inc. on April 15, 2020 for the year ended December 31, 2019.
There are a variety of other forms and filings we are required to file as a publicly traded company, such as registration statements, various reports of transactions by insiders and proxy statements. The button below gives access to all of our filings with the SEC as a publicly reporting company.
Mr. James Sapirstein Chairman
December 14, 2018
Mr. Sapirstein, who has been appointed Executive Chairman, is a highly-regarded pharmaceutical industry executive with more than 35 years of success in building companies and leading the commercial launch of nearly two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. He has worked at major pharmaceutical companies including Bristol-Myers Squibb, Hoffmann-LaRoche and Eli Lilly, and has led commercial teams for successful biotech companies such as Gilead Sciences and Serono Laboratories. In recent years, Mr. Sapirstein has been the founding CEO of the following early-stage biotech companies - Tobira Therapeutics, Alliqua Therapeutics and most recently, Contravir Pharmaceuticals, where he defined and executed corporate strategy, raised significant capital, advanced drug development programs, and built shareholder value.
Dr. Neil J. Campbell, CEO and President
November 1, 2020
Dr. Campbell is President & CEO of Marizyme, Inc. and a member of the Board of Directors. Dr Campbell currently serves as Chairman of Mosaigen, a commercial development company and RespaRx, a medical device company. Dr. Campbell has over 30 years of successful experience with public and private companies in the life sciences, medical, healthtech, nanotechnology, artificial intelligence, and high-performance computing technologies. Previously, Dr. Campbell was Chairman, CEO, and founder of Celios, a respiratory device company that was acquired by a private investment group and is now selling his proprietary technologies on national television. Prior to founding Celios, Dr. Campbell was co-founder, President and CEO of Helomics, a personalized healthcare company focused on next-generation therapeutics and diagnostics. Dr. Campbell has also held academic positions at Johns Hopkins University and Medical Institutes, Hong Kong University of Science and Tech (HKUST), University of Liverpool (UK), University of Baltimore and Duquesne University. Dr. Campbell is a veteran of the U.S. Air Force.
Dr. Satish Chandran, President and Chief Operating Officer
September 8, 2020
Dr. Satish Chandran is a distinguished biotech veteran with nearly 30 years of significant leadership experience in biotechnology. Previously, Dr. Chandran was Director of the Center for Excellence for Biopharmaceutical Research & Development and Professor of Pharmaceutics at North Dakota State University, the Chief Technology Officer of the Nucleic Acid-Based Therapeutics OTU Unit in the BioTherapeutics Division at Pfizer, in Cambridge MA. While at Pfizer, he was also Professor at the Institute for Hepatitis and Virus Research in Doylestown, PA, USA. Previous to Pfizer, he was also Chief Operating Officer and Chief Scientific Officer at Nucleonics, in Horsham PA, the first RNAi based Biotechnology Company he co-founded while on the faculty at Thomas Jefferson University's Biochemistry Department.
Dr. Catherine J. Pachuk, Chief Science Officer
September 8, 2020
Dr. Pachuk has over twenty-five years R&D leadership experience in the pharmaceutical and biotech sectors with expertise in both drug, device and vaccine development with significant experience in nucleic-acid based therapeutic platforms including ASO, RNAi and nucleic-acid based vaccines. Her key areas of therapeutic focus are viral diseases including Hepatitis B, Hepatitis C, and Coronavirus, metabolic disease, HCC and indications associated with Ischemia Reperfusion Injury. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. She received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. She also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in Medical Devices and Pharmaceuticals.
Bruce Harmon, Chief Financial Officer
September 1, 2020
Mr. Harmon has more than 40 years' experience as a financial professional working with Fortune 500 companies to startups, both public and private, and including biotech and pharmaceutical companies. In his career, he has served as chief financial officer, chief executive officer, director, chairman and audit chairman of various public companies on the OTC and as corporate controller of a NASDAQ company in the 1990s. Mr. Harmon served as interim Chief Financial Officer for a pharmaceutical company from 2002 through 2003. Currently, Mr. Harmon owns a consulting firm, Lakeport Business Services, Inc., founded in 2009, which has provided CFO services to more than 100 companies. Through his firm, he currently serves as the Chief Financial Officer of Dale Biotech, LLC (since 2019), a biotech company, and Chief Financial Officer for A Legacy Genetics, Inc. (since 2020), a cattle company. In the past five years, Mr. Harmon has served as Chief Financial Officer of Rhamnolipid, Inc. (2010-2020), a biotech company. In 2005, at the invitation of the Environmental Programmé, Mr. Harmon and two others presented a sustainable green housing option to 84 delegates at the United Nations. Mr. Harmon has been the key financial person involved in 15 companies going public from an IPO (NASDAQ) to reverse mergers. Mr. Harmon holds a B.S. degree in Accounting from Missouri State University.
Terry Brostowin, Esq., Board Member
August 27, 2020
Mr. Brostowin, a Director, is an accomplished attorney admitted to the Federal Courts in both the Eastern and Southern Districts of New York. He has extensive expertise in contracts and commercial litigation. Mr. Brostowin has advised the New York City Mayor’s office on judicial appointments and was a compliance specialist ensuring the agency followed court ordered activities and ensured the financial integrity of the Financial Systems Division accounting and budgetary systems. Mr. Brostowin has been affiliated with the law firm Brostowin & Associates, PC, since 2009. From 2002 to 2009, Mr. Brostowin was affiliated with the law firm Conway & Brostowin, LLC.
March 2018 – Marizyme Founded
We are a Nevada corporation originally incorporated on March 20, 2007, under the name SWAV Enterprises, Ltd. On September 6, 2010, our name was changed to GBS Enterprises Incorporated, and on March 21, 2018, we changed our name to Marizyme, Inc.
September 2018 – Krillase Tech Acquired
On September 12, 2018, we consummated an asset acquisition with ACB Holding AB, a Swedish corporation, and acquired all right, title and interest in the Krillase technology in exchange for 16.98 million unregistered shares of our common stock.
November 2019 – Somahlution License
In November 2019, we signed an initial licensing and commercialization agreement with Somahlution LLC, the owner and developer of the DuraGraft platform.
December 2019 – Somahlution Tech
In December 2019, we entered into an agreement to purchase all of the Somahlution assets, including the DuraGraft platform whose technology can be applied to prevent ischemic injury to tissues and organs.
July 2020 – Somahlution Purchased
In July of 2020 we completed the purchase of Somahlution assets in exchange for shares of our common stock.
August 2020 – Equity Financing Initial Close
August 2020 we closed our initial exempt offering of unregistered common stock for gross proceeds of approximately $5,562,580
Today – Partnering, Commercializing
Our daily focus is cost effectively commercializing life science assets we've acquired or partnered on and finding new prospective assets that fit well with our approach.